UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations

Journal of the Formosan Medical Association, 2020-07, Vol.119 (7), p.1135-1157

2020

Volltextzugriff (PDF)

Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response

Alimentary pharmacology & therapeutics, 2024-03, Vol.59 (6), p.742-751

2024

Volltextzugriff (PDF)

Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis

PloS one, 2017-09, Vol.12 (9), p.e0183851-e0183851

2017

Volltextzugriff (PDF)

A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment

Journal of the Formosan Medical Association, 2024-01, Vol.123 (1), p.55-61

2024

Volltextzugriff (PDF)

Patient‐centered and integrated outreach care for chronic hepatitis C patients with serious mental illness in Taiwan

The Kaohsiung journal of medical sciences, 2024-01, Vol.40 (1), p.86-93

2024

Volltextzugriff (PDF)

Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients

Journal of hepatology, 2009-04, Vol.50 (4), p.712-718

2009

Volltextzugriff (PDF)

Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients

Scientific reports, 2017-06, Vol.7 (1), p.3718-9, Article 3718

2017

Volltextzugriff (PDF)

Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection

Gastroenterology (New York, N.Y. 1943), 2010-04, Vol.138 (4), p.1365-1373.e2

2010

Volltextzugriff (PDF)

Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

Journal of hepatology, 2012-01, Vol.56 (1), p.34-40

2012

Volltextzugriff (PDF)

Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C

Journal of the Formosan Medical Association, 2021-03, Vol.120 (3), p.956-964

2021

Volltextzugriff (PDF)

The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents

The Kaohsiung journal of medical sciences, 2017-11, Vol.33 (11), p.567-571

2017

Volltextzugriff (PDF)

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

Journal of hepatology, 2017-05, Vol.66 (5), p.910-918

2017

Volltextzugriff (PDF)

Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions

Journal of the Formosan Medical Association, 2019-02, Vol.118 (2), p.556-564

2019

Volltextzugriff (PDF)

Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment

EBioMedicine, 2017-02, Vol.15 (C), p.81-89

2017

Volltextzugriff (PDF)

A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan

The Kaohsiung journal of medical sciences, 2017-01, Vol.33 (1), p.44-49

2017

Volltextzugriff (PDF)

Glucose abnormalities in hepatitis C virus infection

The Kaohsiung journal of medical sciences, 2013-02, Vol.29 (2), p.61-68

2013

Volltextzugriff (PDF)

Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection

Antiviral research, 2014-05, Vol.105, p.135-142

2014

Volltextzugriff (PDF)

Chronic hepatitis C infection in the elderly

The Kaohsiung journal of medical sciences, 2011-12, Vol.27 (12), p.533-537

2011

Volltextzugriff (PDF)

The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C

Journal of the Formosan Medical Association, 2018-01, Vol.117 (1), p.14-23

2018

Volltextzugriff (PDF)

Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial)

PloS one, 2023-05, Vol.18 (5), p.e0285725-e0285725

2023

Volltextzugriff (PDF)

Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection

The Kaohsiung journal of medical sciences, 2017-06, Vol.33 (6), p.284-289

2017

Volltextzugriff (PDF)

Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication

Journal of hepatology, 2014-07, Vol.61 (1), p.67-74

2014

Volltextzugriff (PDF)

2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population

Journal of the Formosan Medical Association, 2020-06, Vol.119 (6), p.1019-1040

2020

Volltextzugriff (PDF)

Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort

Journal of the Formosan Medical Association, 2018-01, Vol.117 (1), p.54-62

2018

Volltextzugriff (PDF)

Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection

The Kaohsiung journal of medical sciences, 2015-05, Vol.31 (5), p.271-277

2015

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

ThemaHepatitis C, Chronic - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(45)

Sprache

Englisch
(45)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(45)
Science & Technology
(45)
Life Sciences & Biomedicine
(39)
Antiviral Agents - Therapeutic Use
(34)
Female
(33)
Male
(32)
Middle Aged
(31)
Adult
(22)
Aged
(22)
Genotype
(21)
Hepacivirus - Genetics
(21)
Hepatitis C, Chronic - Virology
(16)
Interferon-Alpha - Therapeutic Use
(16)
Ribavirin - Therapeutic Use
(16)
Drug Therapy, Combination
(14)
General & Internal Medicine
(14)
Hepatitis C
(14)
Medicine, General & Internal
(14)
Polyethylene Glycols - Therapeutic Use
(13)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations

Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response

Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis

A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment

Patient‐centered and integrated outreach care for chronic hepatitis C patients with serious mental illness in Taiwan

Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients

Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients

Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection

Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C

The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions

Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment

A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan

Glucose abnormalities in hepatitis C virus infection

Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection

Chronic hepatitis C infection in the elderly

The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C

Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial)

Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection

Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication

2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population

Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort

Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection

Aktive Filter

Suchergebnisse filtern